ICU Medical: Q3 Earnings Snapshot

ICU Medical (ICUI) reported Q3 2026 adjusted EPS of $2.44, up 20% YoY, with adjusted EBITDA at $114M. Revenue growth was driven by consumables (+5%) and IV systems (+11%), while Vital Care declined (-10%). The company expects full-year EBITDA and EPS to be at the higher end of previous guidance.

ICU Medical Inc reported Q3 2026 earnings with 11% growth in Infusion Systems, driven by competitive wins and customer utilization. The company aims for a 43% gross margin by 2027, with potential for earlier achievement. FDA requested additional testing for MedFusion 5,000 syringe pump and ambulatory pump submissions. Management discussed macroeconomic challenges, currency impacts, and strategic initiatives like the Otsuka joint venture.

ICU Medical (ICUI) reported Q3 earnings, noting delayed Infusion Systems volume and revised growth expectations. Vital Care revenue declined 12% due to logistics issues, with full-year decline expected to be larger than anticipated. Adjusted gross margin expanded to 42%, with debt reduction continuing. The company maintained 2026 guidance but lowered capital spending forecasts.

ICU Medical (ICUI) reported Q3 EPS of $2.44, beating estimates by $0.36, with revenue of $556.22M, slightly above expectations. The stock is down 9.16% over 3 months but up 19.61% year-over-year. InvestingPro rates its financial health as good. The company has seen 5 positive EPS revisions in the last 90 days.

ICU Medical (ICUI) reported Q3 2026 revenue of $556M, up 5% organically. CEO Vivek Jain expects 2026 EBITDA and EPS to be near the high end of the $415M-$435M and $8.60-$9 ranges, respectively, as logistics normalize. Adjusted gross margins were 42%.

ICU Medical reported 3Q 2026 revenue of $560.44M, up 4.4% YoY, with net income of $26.85M, reversing a prior-year loss. Growth in Consumables and Infusion Systems offset a decline in Vital Care. Gross margin improved to 41.9% due to tariff refunds and price increases, according to the company.